NCT04756726

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 224 (estimated)
• Sponsor: C4 Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.

Conditions

• Multiple Myeloma
• Lymphoma, Non-Hodgkin's

Interventions

Type	Name	Description
DRUG	cemsidomide	oral cemsidomide
DRUG	Dexamethasone Oral	oral dexamethasone \[ ≤75 years old: 40 mg once per week (QW) on days 1, 8, 15, and 22; \>75 Years old: 20 mg QW on days 1, 8, 15, and 22\]

Timeline

• Start date: 2021-04-27
• Primary completion: 2026-09-30
• Completion: 2026-12-31
• First posted: 2021-02-16
• Last updated: 2026-03-25

Locations

13 sites across 1 country: United States

Regulatory

• FDA-regulated drug study